Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma

Although chimeric antigen receptor T (CAR-T) cell therapy has been indicated to be effective in treating relapsed or refractory multiple myeloma (R/R MM), severe hematological toxicity (HT) remains an intractable issue. This study enrolled 54 patients with R/R MM following combined infusion of anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hujun, Zhao, Lina, Sun, Zengtian, Yao, Yue, Li, Li, Wang, Jiaojiao, Hua, Tian, Ji, Shengwei, Wang, Shiyuan, Cheng, Hai, Shi, Ming, Li, Zhenyu, Zeng, Lingyu, Wu, Qingyun, Qiao, Jianlin, Chen, Chong, Zheng, Junnian, Cao, Jiang, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623176/
https://www.ncbi.nlm.nih.gov/pubmed/36330523
http://dx.doi.org/10.3389/fimmu.2022.1019548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623176/
https://www.ncbi.nlm.nih.gov/pubmed/36330523
http://dx.doi.org/10.3389/fimmu.2022.1019548

Ejemplares similares